What is Jin Medical's earnings per share (EPS)?

Jin Medical (ZJYL) reported diluted earnings per share of $0.01 for fiscal year 2025. This represents a -50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jin Medical Financials

ZJYL

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE September

This page shows Jin Medical (ZJYL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 30/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Jin Medical has an operating margin of 2.9%, meaning the company retains $3 of operating profit per $100 of revenue. This below-average margin results in a low score of 29/100, suggesting thin profitability after operating expenses. This is down from 15.5% the prior year.

Growth

Jin Medical's revenue declined 12% year-over-year, from $23.5M to $20.7M. This contraction results in a growth score of 13/100.

Leverage

Jin Medical carries a low D/E ratio of 0.80, meaning only $0.80 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Jin Medical's current ratio of 1.86 indicates adequate short-term liquidity, earning a score of 33/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Jin Medical generated $2.9M in operating cash flow, capex of $6.6M consumed most of it, leaving -$3.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Jin Medical generates a 4.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 20/100. This is down from 12.8% the prior year.

Altman Z-Score Grey Zone

1.83

Jin Medical scores 1.83, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Neutral

4/9

Jin Medical passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.44x

For every $1 of reported earnings, Jin Medical generates $2.44 in operating cash flow ($2.9M OCF vs $1.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20.7M

YoY-12.0%

Jin Medical generated $20.7M in revenue in fiscal year 2025. This represents a decrease of 12.0% from the prior year.

EBITDA

$852K

YoY-78.0%

Jin Medical's EBITDA was $852K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 78.0% from the prior year.

Net Income

$1.2M

YoY-67.6%

Jin Medical reported $1.2M in net income in fiscal year 2025. This represents a decrease of 67.6% from the prior year.

EPS (Diluted)

$0.01

YoY-50.0%

Jin Medical earned $0.01 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 50.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$3.7M

YoY-175.6%

Jin Medical generated -$3.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 175.6% from the prior year.

Cash & Debt

$7.5M

YoY-8.3%

Jin Medical held $7.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

157M

YoY+0.0%

Jin Medical had 157M shares outstanding in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Margins & Returns

Gross Margin

29.2%

YoY-11.2pp

Jin Medical's gross margin was 29.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 11.2 percentage points from the prior year.

Operating Margin

2.9%

YoY-12.5pp

Jin Medical's operating margin was 2.9% in fiscal year 2025, reflecting core business profitability. This is down 12.5 percentage points from the prior year.

Net Margin

5.8%

YoY-9.9pp

Jin Medical's net profit margin was 5.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 9.9 percentage points from the prior year.

Return on Equity

4.0%

YoY-8.7pp

Jin Medical's ROE was 4.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 8.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.6M

YoY+4.0%

Jin Medical invested $1.6M in research and development in fiscal year 2025. This represents an increase of 4.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$6.6M

YoY+4473.9%

Jin Medical invested $6.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 4473.9% from the prior year.

ZJYL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	$20.7M-12.0%	$23.5M+18.6%	$19.8M+3.3%	$19.2M-7.6%	$20.8M
Cost of Revenue	$14.4M+4.0%	$13.9M+8.1%	$12.9M+0.2%	$12.8M-10.9%	$14.4M
Gross Profit	$6.0M-36.4%	$9.5M+40.1%	$6.8M+9.5%	$6.2M-2.6%	$6.4M
R&D Expenses	$1.6M+4.0%	$1.5M-3.0%	$1.5M-18.5%	$1.9M+20.8%	$1.6M
SG&A Expenses	$2.5M-22.3%	$3.3M+69.8%	$1.9M+8.3%	$1.8M+6.0%	$1.7M
Operating Income	$608K-83.3%	$3.6M+26.9%	$2.9M+34.6%	$2.1M-19.0%	$2.6M
Interest Expense	N/A	N/A	$183K+0.6%	$182K+2013.2%	-$9K
Income Tax	$215K-71.9%	$764K+122.2%	$344K+851.8%	$36K-85.5%	$249K
Net Income	$1.2M-67.6%	$3.7M+27.7%	$2.9M+6.3%	$2.7M+2.8%	$2.6M
EPS (Diluted)	$0.01-50.0%	$0.020.0%	$0.020.0%	$0.020.0%	$0.02

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ZJYL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$53.4M+16.5%	$45.8M+39.2%	$32.9M+57.1%	$20.9M	N/A
Current Assets	$44.1M+3.1%	$42.8M+37.6%	$31.1M+64.6%	$18.9M	N/A
Cash & Equivalents	$7.5M-8.3%	$8.1M+17.4%	$6.9M+44.6%	$4.8M+30.5%	$3.7M
Inventory	$4.9M-4.8%	$5.2M+2.4%	$5.1M-24.9%	$6.7M	N/A
Accounts Receivable	$5.8M-1.8%	$5.9M+80.1%	$3.3M-14.3%	$3.8M	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.8M+38.0%	$17.2M+93.3%	$8.9M+56.5%	$5.7M	N/A
Current Liabilities	$23.8M+38.7%	$17.2M+92.2%	$8.9M+56.5%	$5.7M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$29.6M+2.9%	$28.8M+20.2%	$24.0M+57.4%	$15.2M+8.6%	$14.0M
Retained Earnings	$20.9M+4.6%	$20.0M+18.3%	$16.9M+17.5%	$14.4M	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Total Assets	$53.4M+10.0%	$48.5M+5.9%	$45.8M+11.3%	$41.2M+25.1%	$32.9M+6.1%	$31.0M+48.2%	$20.9M
Current Assets	$44.1M+0.8%	$43.8M+2.3%	$42.8M+12.1%	$38.2M+22.7%	$31.1M+7.0%	$29.1M+53.9%	$18.9M
Cash & Equivalents	$7.5M-33.0%	$11.1M+36.8%	$8.1M-8.3%	$8.9M+28.1%	$6.9M+188.7%	$2.4M-49.9%	$4.8M
Inventory	$4.9M+10.5%	$4.5M-13.9%	$5.2M+13.9%	$4.5M-10.1%	$5.1M-22.4%	$6.5M-3.2%	$6.7M
Accounts Receivable	$5.8M+37.0%	$4.2M-28.3%	$5.9M+53.3%	$3.9M+17.5%	$3.3M+1024.9%	$292K-92.4%	$3.8M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.8M+14.6%	$20.8M+20.4%	$17.2M+14.9%	$15.0M+68.1%	$8.9M+19.4%	$7.5M+31.1%	$5.7M
Current Liabilities	$23.8M+14.8%	$20.7M+20.9%	$17.2M+15.7%	$14.8M+66.1%	$8.9M+19.4%	$7.5M+31.1%	$5.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$29.6M+6.2%	$27.9M-3.1%	$28.8M+9.8%	$26.2M+9.4%	$24.0M+1.8%	$23.5M+54.5%	$15.2M
Retained Earnings	$20.9M+5.4%	$19.9M-0.8%	$20.0M+8.5%	$18.5M+9.0%	$16.9M+5.8%	$16.0M+11.0%	$14.4M

ZJYL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	$2.9M+340.5%	-$1.2M-138.9%	$3.1M+96.5%	$1.6M-72.9%	$5.8M
Capital Expenditures	$6.6M+4473.9%	$145K+27.2%	$114K+183.7%	$40K-6.3%	$43K
Free Cash Flow	-$3.7M-175.6%	-$1.4M-145.2%	$3.0M+94.3%	$1.5M-73.4%	$5.8M
Investing Cash Flow	-$10.8M-13.4%	-$9.5M-23.1%	-$7.7M-6293.7%	-$121K+88.7%	-$1.1M
Financing Cash Flow	$7.4M-36.9%	$11.7M+68.6%	$6.9M+5571.2%	$122K+104.2%	-$2.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ZJYL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	29.2%-11.2pp	40.4%+6.2pp	34.2%+1.9pp	32.3%+1.7pp	30.6%
Operating Margin	2.9%-12.5pp	15.5%+1.0pp	14.5%+3.4pp	11.1%-1.6pp	12.7%
Net Margin	5.8%-9.9pp	15.6%+1.1pp	14.5%+0.4pp	14.1%+1.4pp	12.7%
Return on Equity	4.0%-8.7pp	12.8%+0.8pp	12.0%-5.8pp	17.8%-1.0pp	18.8%
Return on Assets	2.2%-5.8pp	8.0%-0.7pp	8.8%-4.2pp	12.9%	N/A
Current Ratio	1.86-0.6	2.50-1.0	3.49+0.2	3.31	N/A
Debt-to-Equity	0.80+0.2	0.60+0.2	0.370.0	0.37	N/A
FCF Margin	-18.0%-12.3pp	-5.8%-20.8pp	15.1%+7.1pp	8.0%-19.9pp	27.9%

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.86-0.3	2.11-0.4	2.50-0.1	2.58-0.9	3.49-0.4	3.89+0.6	3.31
Debt-to-Equity	0.80+0.1	0.74+0.1	0.60+0.0	0.57+0.2	0.37+0.1	0.32-0.1	0.37
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Zentek Ltd ZTEK

$59.9M

Pro-Dex Inc Colo PDEX

$159.6M

Utah Med Prods UTMD

$202.2M

Koru Med Sys KRMD

$196.6M

ANTERIS TECHNOLOGIES GLOBAL AVR

$517.3M

Frequently Asked Questions

What is Jin Medical's annual revenue?

Jin Medical (ZJYL) reported $20.7M in total revenue for fiscal year 2025. This represents a -12.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Jin Medical's revenue growing?

Jin Medical (ZJYL) revenue declined by 12% year-over-year, from $23.5M to $20.7M in fiscal year 2025.

Is Jin Medical profitable?

Yes, Jin Medical (ZJYL) reported a net income of $1.2M in fiscal year 2025, with a net profit margin of 5.8%.

What is Jin Medical's EBITDA?

Jin Medical (ZJYL) had EBITDA of $852K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Jin Medical's gross margin?

Jin Medical (ZJYL) had a gross margin of 29.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Jin Medical's operating margin?

Jin Medical (ZJYL) had an operating margin of 2.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Jin Medical's net profit margin?

Jin Medical (ZJYL) had a net profit margin of 5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Jin Medical's return on equity (ROE)?

Jin Medical (ZJYL) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Jin Medical's free cash flow?

Jin Medical (ZJYL) generated -$3.7M in free cash flow during fiscal year 2025. This represents a -175.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Jin Medical's operating cash flow?

Jin Medical (ZJYL) generated $2.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Jin Medical's total assets?

Jin Medical (ZJYL) had $53.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Jin Medical's capital expenditures?

Jin Medical (ZJYL) invested $6.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Jin Medical spend on research and development?

Jin Medical (ZJYL) invested $1.6M in research and development during fiscal year 2025.

How many shares does Jin Medical have outstanding?

Jin Medical (ZJYL) had 157M shares outstanding as of fiscal year 2025.

What is Jin Medical's current ratio?

Jin Medical (ZJYL) had a current ratio of 1.86 as of fiscal year 2025, which is generally considered healthy.

What is Jin Medical's debt-to-equity ratio?

Jin Medical (ZJYL) had a debt-to-equity ratio of 0.80 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jin Medical's return on assets (ROA)?

Jin Medical (ZJYL) had a return on assets of 2.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jin Medical's Altman Z-Score?

Jin Medical (ZJYL) has an Altman Z-Score of 1.83, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Jin Medical's Piotroski F-Score?

Jin Medical (ZJYL) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jin Medical's earnings high quality?

Jin Medical (ZJYL) has an earnings quality ratio of 2.44x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Jin Medical?

Jin Medical (ZJYL) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.